GILDGILEAD SCIENCES, INC.

Nasdaq gilead.com


$ 64.60 $ -0.34 (-0.52 %)    

Thursday, 09-May-2024 15:59:57 EDT
QQQ $ 441.33 $ 0.96 (0.22 %)
DIA $ 394.43 $ 3.52 (0.9 %)
SPY $ 520.56 $ 2.98 (0.58 %)
TLT $ 90.69 $ 0.44 (0.49 %)
GLD $ 216.93 $ 3.37 (1.58 %)
$ 64.58
$ 65.09
$ 0.00 x 0
$ 0.00 x 0
$ 64.52 - $ 65.09
$ 64.33 - $ 86.97
6,048,572
na
80.53B
$ 0.34
$ 166.04
TBD
na
na ($ 0.05)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-23-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-04-2023 06-30-2023 10-Q
5 05-03-2023 03-31-2023 10-Q
6 02-22-2023 12-31-2022 10-K
7 11-02-2022 09-30-2022 10-Q
8 08-08-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 02-23-2022 12-31-2021 10-K
11 11-03-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-04-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-06-2020 03-31-2020 10-Q
18 02-25-2020 12-31-2019 10-K
19 11-05-2019 09-30-2019 10-Q
20 08-06-2019 06-30-2019 10-Q
21 05-08-2019 03-31-2019 10-Q
22 02-26-2019 12-31-2018 10-K
23 11-06-2018 09-30-2018 10-Q
24 08-06-2018 06-30-2018 10-Q
25 05-09-2018 03-31-2018 10-Q
26 02-27-2018 12-31-2017 10-K
27 11-07-2017 09-30-2017 10-Q
28 08-07-2017 06-30-2017 10-Q
29 05-10-2017 03-31-2017 10-Q
30 02-27-2017 12-31-2016 10-K
31 11-07-2016 09-30-2016 10-Q
32 08-05-2016 06-30-2016 10-Q
33 05-06-2016 03-31-2016 10-Q
34 02-24-2016 12-31-2015 10-K
35 11-04-2015 09-30-2015 10-Q
36 08-05-2015 06-30-2015 10-Q
37 05-08-2015 03-31-2015 10-Q
38 02-25-2015 12-31-2014 10-K
39 11-05-2014 09-30-2014 10-Q
40 08-04-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 barclays-maintains-equal-weight-on-gilead-sciences-lowers-price-target-to-76

Barclays analyst Carter Gould maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and lowers the price target from $...

 will-earnings-cheer-continue-to-buoy-markets-apple-amazon-pfizer-coinbase-lead-flurry-of-q1-reports-this-week

With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and...

 td-cowen-maintains-buy-on-gilead-sciences-lowers-price-target-to-85

TD Cowen analyst Tyler Van Buren maintains Gilead Sciences (NASDAQ:GILD) with a Buy and lowers the price target from $90 to ...

 morgan-stanley-maintains-equal-weight-on-gilead-sciences-lowers-price-target-to-78

Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and lowers the price tar...

 rbc-capital-maintains-sector-perform-on-gilead-sciences-lowers-price-target-to-74

RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and lowers the price target...

 fda-approves-biktarvy-label-update-with-data-for-pregnant-adults-with-hiv-perinatal-guidelines-recognize-biktarvy-as-alternative-regimen-for-use-during-pregnancy-and-for-those-trying-to-conceive

– Additional Data in Pregnant Adults Who Are Virologically Suppressed Reinforce Safety and Tolerability Profile of Biktarvy in ...

 needham-reiterates-hold-on-gilead-sciences

Needham analyst Joseph Stringer reiterates Gilead Sciences (NASDAQ:GILD) with a Hold.

 gilead-sciences-q1-2024-adj-eps-132-beats-149-estimate-sales-610b-miss-634b-estimate

Gilead Sciences (NASDAQ:GILD) reported quarterly losses of $(1.32) per share which beat the analyst consensus estimate of $(1.4...

 stocks-drop-tech-tumbles-with-metas-weak-outlook-q1-stagflation-fears-gold-miners-advance-whats-driving-markets-thursday

Wall Street suffers a double blow in Thursday’s session, as softer-than-expected revenue forecasts from Meta Platforms Inc. (NA...

 us-stocks-brace-for-negative-start-amid-tech-earnings-disappointments-caution-ahead-of-data-worst-of-this-two-week-decline-is-behind-us-says-analyst

The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platfor...

 hsbc-upgrades-gilead-sciences-to-hold-announces-69-price-target

HSBC analyst Morten Herholdt upgrades Gilead Sciences (NASDAQ:GILD) from Reduce to Hold and announces $69 price target.

 why-is-penny-stock-hookipa-pharma-trading-higher-on-wednesday

HOOKIPA Pharma secures FDA clearance for its innovative HB-700 therapeutic vaccine targeting KRAS-mutated cancers. Learn about ...

 can-magnificent-7-help-script-market-turnaround-earnings-pick-up-pace-with-microsoft-meta-alphabet-and-tesla-expected-this-week

Corporate profit growth rose in Q3 2023 and is expected to continue in Q1.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION